Pharma

Pharmalot By Ed Silverman

Race is often overlooked in key clinical trial data used to win new drug approvals in Europe

Pharmalot By Ed Silverman

FDA warns Miami University contract testing lab over falsified data, poor quality control

Pharmalot By Ed Silverman

Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver

Pharmalot By Ed Silverman

A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO

First Opinion By Els Torreele

Global health should not be determined by pharma investors and shareholders

Pharmalot By Ed Silverman

Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels

Pharmalot By Ed Silverman

Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process

Pharmalot By Ed Silverman

U.N. committee urges wealthy nations to honor human rights and widen access to Covid vaccines

Pharmalot By Ed Silverman

Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members

Pharmalot By Ed Silverman

U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency

Pharma By Matthew Herper

Pfizer vaccine chief Kathrin Jansen, who led Covid effort, to retire

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare

Pharma By Ed Silverman

The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant

Pharmalot By Ed Silverman

California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?

Pharmalot By Ed Silverman

Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing

Pharma By Ed Silverman

Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices

Pharmalot By Ed Silverman

Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims

Pharma By Ed Silverman

Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law

Pharmalot By Ed Silverman

Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?

Pharmalot By Ed Silverman

Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review

Pharmalot By Ed Silverman

One in four pharma status reports on follow-up trials are late or aren’t filed

Pharmalot By Ed Silverman

Pharma R&D payments to European researchers are like ‘dark money’

Pharmalot By Ed Silverman

Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms

Pharmalot By Ed Silverman

Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging

Pharmalot By Ed Silverman

U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies

Pharmalot By Ed Silverman

Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions